A new trading day began on Friday, with Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock price down -0.54% from the previous day of trading, before settling in for the closing price of $5.52. RXRX’s price has ranged from $3.79 to $12.36 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -35.28%. Meanwhile, its annual earnings per share averaged 6.24%. With a float of $332.98 million, this company’s outstanding shares have now reached $425.48 million.
Recursion Pharmaceuticals Inc (RXRX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Recursion Pharmaceuticals Inc is 23.39%, while institutional ownership is 53.79%. The most recent insider transaction that took place on Sep 25 ’25, was worth 476,000. In this transaction Chief Executive Officer of this company sold 100,000 shares at a rate of $4.76, taking the stock ownership to the 954,229 shares. Before that another transaction happened on Sep 25 ’25, when Company’s Officer proposed sale 100,000 for $4.76, making the entire transaction worth $476,000.
Recursion Pharmaceuticals Inc (RXRX) Recent Fiscal highlights
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.34 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.31% during the next five years compared to -35.28% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Here are Recursion Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 36.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.28 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Looking closely at Recursion Pharmaceuticals Inc (NASDAQ: RXRX), its last 5-days average volume was 44.25 million, which is a jump from its year-to-date volume of 25.14 million. As of the previous 9 days, the stock’s Stochastic %D was 83.01%.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 47.96%, which indicates a significant decrease from 81.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.30 in the past 14 days, which was lower than the 0.35 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.14, while its 200-day Moving Average is $5.85. However, in the short run, Recursion Pharmaceuticals Inc’s stock first resistance to watch stands at $5.68. Second resistance stands at $5.87. The third major resistance level sits at $6.04. If the price goes on to break the first support level at $5.32, it is likely to go to the next support level at $5.15. Now, if the price goes above the second support level, the third support stands at $4.96.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
With a market capitalization of 2.39 billion, the company has a total of 434,152K Shares Outstanding. Currently, annual sales are 58,840 K while annual income is -463,660 K. The company’s previous quarter sales were 19,220 K while its latest quarter income was -171,900 K.
